HEOR

News

NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.

Market Access

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

News

ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.

News

Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.

News

Several years after other UK nations, people living with multiple sclerosis in England are finally able to get NHS treatment with fampridine.